Skip to content

VAXCONSULT

Active
Private limited companyfounded 20242 yrs activeJacques Pasturlaan 160, 1180 Ukkel, BelgiumKBO/BCE: BE 1010.543.129
Summary

VAXCONSULT has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €268k and a net result of €128k. Its solvency ranks better than 70% of 31791 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.7% (low).

Checked score

Score 2025
Axes · tick = 2024
Profitability100=
Solvency100=
Growth52
Track record82
Bankruptcy probability, 12 months
0.7% Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €24k at 30 days only on tighter terms
Liquidity ample (current ratio 3.97 against 4.75 in 2024; short-term debt: 25.2% and cash: 71.6% of total assets), and 25.2% of the assets are financed with debt.
Credit check for your own amount and term

Open the credit simulator : see how the verdict changes with amount, term and advance.

Signals

Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 70
Relative position
BE, all sectors
reference
Activities of head offices; management consultancy activities (NACE 70)
about 69% fewer bankruptcies
← fewer bankruptcies more bankruptcies →
raises risk · Young company
A young company has little track record yet and statistically fails more often than an established one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 2 years 0 10 y
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
74.8%
Return on assets
35.6%
Age of the figures
9 mo
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-08-2026, 27 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 2 filings
Deviation from the deadline
2025
27 d late
2024
31 d late
← before the deadline after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Position in the running window
25-09-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

On 20 June 2024, VAXCONSULT was incorporated as a Private limited company.1 The company has filed 2 sets of annual accounts, the latest for fiscal year 2025.2

  1. 1Crossroads Bank for Enterprises
  2. 2National Bank, annual accounts 2025

Go further with this company

Is this your company? See how customers and banks see it.

Financials · fiscal year 2025, micro schema

Equity
€268k▲ 80.4%
2024 · €149k
Total assets
€359k▲ 90.3%
2024 · €189k
Net result
€128k▼ 8.1%
2024 · €139k
Working capital
€268k▲ 80.4%
2024 · €149k
Trend over the years

Click a name to add, emphasise or remove a line.

Every figure with its change against the fiscal year before
favourable unfavourable
Line20242025
Operating result€178k-€166k▼ 6.8%
Net result€139k-€128k▼ 8.1%
Equity€149k-€268k▲ 80.4%
Total assets€189k-€359k▲ 90.3%
Debt€40k-€90k▲ 127%
Working capital€149k-€268k▲ 80.4%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
€0€50k€100k€150k€200kOperating result 2024: €178k€178kNet result 2024: €139k€139kOperating result 2025: €166k€166kNet result 2025: €128k€128k20242025€0€50k€100k€150k€200kOperating result 2024: €178k€178kNet result 2024: €139k€139kOperating result 2025: €166k€166kNet result 2025: €128k€128k20242025
The operating result falls in 2025; 2025 is 7% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Equity and liabilities €359k
Equity €268k ▲ 80.4%
Debt €90k ▲ 127%
Debt's share of the balance-sheet total rises from 21.1% to 25.2%. Equity and debt are higher.
Key figures and ratios
2025 value · change against 2024
Current ratio
3.97▼
2024 · 4.75
Debt to equity
0.34▲
2024 · 0.27
ROE
47.5%▼
2024 · 93.3%
ROA
35.6%▼
2024 · 73.6%
Debt ≤ 1 year
€90k▲
2024 · €40k
Income taxes
€39k▼
2024 · €40k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 31 lines
Balance sheet Code20242025
Assets
Total assets20/58€189k€359k▲
Current assets29/58€189k€359k▲
Amounts receivable within one year40/41€8k€4k▼
Trade receivables40-€1k
Other amounts receivable41€8k€3k▼
Current investments50/53-€98k
Cash at bank and in hand54/58€181k€257k▲
Equity and liabilities
Total equity and liabilities10/49€189k€359k▲
Equity10/15€149k€268k▲
Contributions10/11€10k€10k=
Profit (loss) carried forward14€139k€258k▲
Amounts payable17/49€40k€90k▲
Amounts payable within one year42/48€40k€90k▲
Trade debts44-€306
Suppliers440/4-€306
Taxes, remuneration and social security45€40k€76k▲
Taxes450/3€40k€76k▲
Other amounts payable47/48-€14k
Income statement Code20242025
Other operating charges640/8-€400
Gross operating margin9900€178k€167k▼
Operating profit (loss)9901€178k€166k▼
Financial income75/76B€941€3k▲
Recurring financial income75€941€3k▲
Financial charges65/66B€732€2k▲
Recurring financial charges65€732€2k▲
Profit (loss) for the period before taxes9903€179k€167k▼
Income taxes67/77€40k€39k▼
Profit (loss) for the period9904€139k€128k▼
Profit (loss) for the period to be appropriated9905€139k€128k▼
Appropriation of the result
Profit (loss) to be appropriated9906€139k€258k▲
Profit (loss) brought forward from the previous period14P-€131k

The notes to these accounts (1 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20242025Change
Other operating charges640/8-€400-
Gross operating margin9900€178k€167k▼ 6.6%
Operating profit (loss)9901€178k€166k▼ 6.8%
Financial income75/76B€941€3k▲ 184%
Recurring financial income75€941€3k▲ 184%
Financial charges65/66B€732€2k▲ 142%
Recurring financial charges65€732€2k▲ 142%
Profit (loss) for the period before taxes9903€179k€167k▼ 6.4%
Income taxes67/77€40k€39k▼ 0.5%
Profit (loss) for the period9904€139k€128k▼ 8.1%
Profit (loss) for the period to be appropriated9905€139k€128k▼ 8.1%
Line20242025Change
Assets
Total assets20/58€189k€359k▲ 90.3%
Current assets29/58€189k€359k▲ 90.3%
Amounts receivable within one year40/41€8k€4k▼ 44.6%
Trade receivables40-€1k-
Other amounts receivable41€8k€3k▼ 61.0%
Current investments50/53-€98k-
Cash at bank and in hand54/58€181k€257k▲ 42.1%
Equity and liabilities
Total equity and liabilities10/49€189k€359k▲ 90.3%
Equity10/15€149k€268k▲ 80.4%
Contributions10/11€10k€10k=
Profit (loss) carried forward14€139k€258k▲ 86.2%
Amounts payable17/49€40k€90k▲ 127%
Amounts payable within one year42/48€40k€90k▲ 127%
Trade debts44-€306-
Suppliers440/4-€306-
Taxes, remuneration and social security45€40k€76k▲ 91.1%
Taxes450/3€40k€76k▲ 91.1%
Other amounts payable47/48-€14k-
Line20242025Change
Profit (loss) for the period9904€139k€128k▼ 8.1%
Operating cash flow (approximation)€139k€128k▼ 8.1%
Change in cash-€76k-

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 31-07-2027
2026
27-08
NBB filing Annual accounts filed
fiscal year 2025 · micro schema · 27 days late
2025
31-12
Financial Equity above €200kEq €268k ▲80.4%
2 profitable years in a row build equity to €268k.
31-08
NBB filing Annual accounts filed
fiscal year 2024 · micro schema · 31 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 1 act read
About the unread acts

We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Ukkel · 1 establishment unit since 2024
seat establishment The establishment unit on the map
Ground area
780 m²
Building footprint
182 m²
Volume, LiDAR
1,301 m³
Parcel 21614H0056/02S064, Brussels · tallest building 9.4 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
VAXCONSULT
Jacques Pasturlaan 160, 1180 UkkelRenting and operating of own or leased residential real estate, excluding social housing
since 20242.365.096.065
1 parcel
Brussels 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
21614H0056/02S064 Brussels 780 m² 1 · 182 m² 9.4 m · 3 fl.
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Recognitions · licences · registrations

Legal Entity Identifier

699400LA7USB73ZFF696
live in the LEI register

Similar companies · same sector, comparable size

Of 82,632 companies in sector 70200 we hold annual accounts for 52,587. 38,660 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification
Legal formPrivate limited company
Founded20-06-2024
Fiscal year end31-12
Activities, NACEBEL 2025
70200Business and other management consultancy
72101Research and development on biotechnology

Scores and ratios are computed by Checked and are not a credit decision.